Novo Nordisk A/S

Industry

  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Digital Health
    • Disease Management

Other Names/Subsidiaries

  • BIOCORP
  • Biocorp Production SA
  • Calibrium
  • Carbometrics
  • Cardior Pharmaceuticals
  • Cardior Pharmaceuticals GmbH
  • Catalent
  • Corvidia Therapeutics
  • Dicerna Pharmaceuticals
  • Embark Biotech
  • Emisphere Technologies
  • FORMA Therapeutics
  • Inversago Pharma
  • KabaFusion
  • MB2
  • Neose Technologies
  • Neotope Neuroscience
  • Novo Holdings A/S
  • Novo Nordisk Pharmaceuticals
  • Pharmaero Aps
  • Xellia Pharmaceuticals ApS
  • Ziylo
See more in Biomedtracker

Latest on Novo Nordisk A/S

Scrip

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Who: Eli Lilly/Juvena Therapeutics What: Juvena will use its AI platform JuvNET to identify stem cell-secreted protein drug candidates to help patients on obesity therapy maintain muscle mass and f

Scrip

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

 
• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Taiho Sends Benz LSD1 Inhibitor Fo

Scrip

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 
• By Eleanor Malone, Edwin Elmhirst, and Kosh Naran

Riding high on the wave of its dual GIP/GLP-1 agonist, tirzepatide, Eli Lilly awarded its CEO the highest total remuneration package of the top 12 big pharma companies in 2024. David Ricks’s total com

Scrip

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

In its sixth cardiometabolic disease deal of 2025, Novo Nordisk – reportedly concerned about its standing in the obesity and diabetes space versus its nearest rival, Eli Lilly – will turn to Deep Ap